President Donald Trump has been vocal about his efforts to lower drug prices through negotiations with pharmaceutical companies over the past year. However, the world’s largest drugmakers show no signs of financial strain from these pressures. On Thursday, three major US drugmakers, Eli Lilly & Co., Merck & Co., and Bristol Myers Squibb Co., reported record quarterly revenue. Each company also raised its annual forecasts, attributing their success to robust demand for new treatments and established blockbusters like Lilly’s weight-loss drug Zepbound.
The strong financial performance suggests that Trump’s pricing initiatives have not yet impacted the bottom lines of these pharmaceutical giants. Eli Lilly & Co. led the charge with record revenue, driven by the popularity of Zepbound. Merck & Co. and Bristol Myers Squibb Co. followed suit, reporting similarly impressive results. The companies’ ability to maintain growth despite regulatory pressures highlights their resilience in the market.
Analysts note that the demand for innovative treatments and long-standing blockbuster drugs continues to outweigh any potential downsides from pricing negotiations. The record revenue and raised forecasts indicate that these companies are well-positioned to navigate the current regulatory landscape. For now, the drugmakers appear unfazed by Trump’s push for lower prices, focusing instead on their strong sales and expanding product lines.